Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Nystagmus in patients with congenital stationary night blindness (CSNB) originates from synchronously firing retinal ganglion cells.

Winkelman BHJ, Howlett MHC, Hölzel MB, Joling C, Fransen KH, Pangeni G, Kamermans S, Sakuta H, Noda M, Simonsz HJ, McCall MA, De Zeeuw CI, Kamermans M.

PLoS Biol. 2019 Sep 12;17(9):e3000174. doi: 10.1371/journal.pbio.3000174. eCollection 2019 Sep.

2.

46th annual congress of the "Arbeitsgemeinschaft Dermatologische Forschung" in Munich, Germany.

Gaffal E, Eming R, Fabri M, Gebhardt C, Stary G, Eyerich S, Hölzel M, Kosnopfel C, Neubert E, Rauer D, Rodríguez E, Thiem A, von Meyenn L, Buhl T.

Exp Dermatol. 2019 Sep;28(9):1094-1099. doi: 10.1111/exd.13990. No abstract available.

PMID:
31463988
3.

Joint reconstruction and classification of tumor cells and cell interactions in melanoma tissue sections with synthesized training data.

Effland A, Kobler E, Brandenburg A, Klatzer T, Neuhäuser L, Hölzel M, Landsberg J, Pock T, Rumpf M.

Int J Comput Assist Radiol Surg. 2019 Apr;14(4):587-599. doi: 10.1007/s11548-019-01919-z. Epub 2019 Feb 16.

4.

Author Correction: Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Feb;566(7745):E10. doi: 10.1038/s41586-019-0958-0.

PMID:
30742076
5.

Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Jan;565(7739):366-371. doi: 10.1038/s41586-018-0812-9. Epub 2018 Dec 31. Erratum in: Nature. 2019 Feb;566(7745):E10.

PMID:
30598548
6.

Altered Notch Signaling in Dowling-Degos Disease: Additional Mutations in POGLUT1 and Further Insights into Disease Pathogenesis.

Ralser DJ, Takeuchi H, Fritz G, Basmanav FB, Effern M, Sivalingam S, El-Shabrawi-Caelen L, Degirmentepe EN, Kocatürk E, Singh M, Booken N, Spierings NMK, Schnabel V, Heineke A, Knuever J, Wolf S, Wehner M, Tronnier M, Leverkus M, Tantcheva-Poór I, Wenzel J, Oji V, Has C, Hölzel M, Frank J, Haltiwanger RS, Betz RC.

J Invest Dermatol. 2019 Apr;139(4):960-964. doi: 10.1016/j.jid.2018.10.030. Epub 2018 Nov 9. No abstract available.

PMID:
30414910
7.

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze HJ, Hölzel M, Roesch A, Kneitz S, Meierjohann S, Bosserhoff A, Binder H, Schartl M.

Oncogene. 2018 Nov;37(47):6136-6151. doi: 10.1038/s41388-018-0385-y. Epub 2018 Jul 11.

PMID:
29995873
8.

In Vivo Labeling by CD73 Marks Multipotent Stromal Cells and Highlights Endothelial Heterogeneity in the Bone Marrow Niche.

Breitbach M, Kimura K, Luis TC, Fuegemann CJ, Woll PS, Hesse M, Facchini R, Rieck S, Jobin K, Reinhardt J, Ohneda O, Wenzel D, Geisen C, Kurts C, Kastenmüller W, Hölzel M, Jacobsen SEW, Fleischmann BK.

Cell Stem Cell. 2018 Feb 1;22(2):262-276.e7. doi: 10.1016/j.stem.2018.01.008.

9.

Eliminating Glutamatergic Input onto Horizontal Cells Changes the Dynamic Range and Receptive Field Organization of Mouse Retinal Ganglion Cells.

Ströh S, Puller C, Swirski S, Hölzel MB, van der Linde LIS, Segelken J, Schultz K, Block C, Monyer H, Willecke K, Weiler R, Greschner M, Janssen-Bienhold U, Dedek K.

J Neurosci. 2018 Feb 21;38(8):2015-2028. doi: 10.1523/JNEUROSCI.0141-17.2018. Epub 2018 Jan 19.

10.

RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.

Glodde N, Hölzel M.

Immunity. 2017 Dec 19;47(6):1007-1009. doi: 10.1016/j.immuni.2017.12.001.

11.

Improved heart repair upon myocardial infarction: Combination of magnetic nanoparticles and tailored magnets strongly increases engraftment of myocytes.

Ottersbach A, Mykhaylyk O, Heidsieck A, Eberbeck D, Rieck S, Zimmermann K, Breitbach M, Engelbrecht B, Brügmann T, Hesse M, Welz A, Sasse P, Wenzel D, Plank C, Gleich B, Hölzel M, Bloch W, Pfeifer A, Fleischmann BK, Roell W.

Biomaterials. 2018 Feb;155:176-190. doi: 10.1016/j.biomaterials.2017.11.012. Epub 2017 Nov 15.

PMID:
29179133
12.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

13.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
14.

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

Layer JP, Kronmüller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, Althoff K, Schramm A, Westermann F, Peifer M, Hartmann G, Tüting T, Kolanus W, Fischer M, Schulte J, Hölzel M.

Oncoimmunology. 2017 Apr 28;6(6):e1320626. doi: 10.1080/2162402X.2017.1320626. eCollection 2017.

15.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

16.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

17.

The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.

Kunz M, Hölzel M.

Cancer Metastasis Rev. 2017 Mar;36(1):53-75. doi: 10.1007/s10555-017-9657-1.

PMID:
28210865
18.

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.

Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR.

Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17.

19.

The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas.

Nettersheim D, Arndt I, Sharma R, Riesenberg S, Jostes S, Schneider S, Hölzel M, Kristiansen G, Schorle H.

Br J Cancer. 2016 Aug 9;115(4):454-64. doi: 10.1038/bjc.2016.187. Epub 2016 Jul 21.

20.

Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis.

Hölzel M, Tüting T.

Trends Immunol. 2016 Jun;37(6):364-374. doi: 10.1016/j.it.2016.03.009. Epub 2016 Apr 15. Review.

PMID:
27151281
21.

A stochastic model for immunotherapy of cancer.

Baar M, Coquille L, Mayer H, Hölzel M, Rogava M, Tüting T, Bovier A.

Sci Rep. 2016 Apr 11;6:24169. doi: 10.1038/srep24169.

22.

Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.

Braegelmann C, Hölzel M, Ludbrook V, Dickson M, Turan N, Ferring-Schmitt S, Sternberg S, Bieber T, Kuhn A, Wenzel J.

Exp Dermatol. 2016 May;25(5):375-9. doi: 10.1111/exd.12986.

PMID:
26910509
23.

Tpbpa-Cre-mediated deletion of TFAP2C leads to deregulation of Cdkn1a, Akt1 and the ERK pathway, causing placental growth arrest.

Sharma N, Kubaczka C, Kaiser S, Nettersheim D, Mughal SS, Riesenberg S, Hölzel M, Winterhager E, Schorle H.

Development. 2016 Mar 1;143(5):787-98. doi: 10.1242/dev.128553. Epub 2016 Jan 25.

24.

Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.

Knappe N, Novak D, Weina K, Bernhardt M, Reith M, Larribere L, Hölzel M, Tüting T, Gebhardt C, Umansky V, Utikal J.

Stem Cells. 2016 Apr;34(4):832-46. doi: 10.1002/stem.2284. Epub 2016 Jan 19.

25.

The experimental power of FR900359 to study Gq-regulated biological processes.

Schrage R, Schmitz AL, Gaffal E, Annala S, Kehraus S, Wenzel D, Büllesbach KM, Bald T, Inoue A, Shinjo Y, Galandrin S, Shridhar N, Hesse M, Grundmann M, Merten N, Charpentier TH, Martz M, Butcher AJ, Slodczyk T, Armando S, Effern M, Namkung Y, Jenkins L, Horn V, Stößel A, Dargatz H, Tietze D, Imhof D, Galés C, Drewke C, Müller CE, Hölzel M, Milligan G, Tobin AB, Gomeza J, Dohlman HG, Sondek J, Harden TK, Bouvier M, Laporte SA, Aoki J, Fleischmann BK, Mohr K, König GM, Tüting T, Kostenis E.

Nat Commun. 2015 Dec 14;6:10156. doi: 10.1038/ncomms10156.

26.

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M.

Nat Commun. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.

27.

A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells.

Hölzel M, Landsberg J, Glodde N, Bald T, Rogava M, Riesenberg S, Becker A, Jönsson G, Tüting T.

Cancer Res. 2016 Jan 15;76(2):251-63. doi: 10.1158/0008-5472.CAN-15-1090. Epub 2015 Oct 28.

28.

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

Papadakis AI, Sun C, Knijnenburg TA, Xue Y, Grernrum W, Hölzel M, Nijkamp W, Wessels LF, Beijersbergen RL, Bernards R, Huang S.

Cell Res. 2015 Apr;25(4):445-58. doi: 10.1038/cr.2015.16. Epub 2015 Feb 6.

29.

IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.

D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, Hölzel M, Ferring-Schmitt S, Sternberg S, Wittmann M, Peters B, Bosio A, Bieber T, Wenzel J.

J Invest Dermatol. 2015 Apr;135(4):1025-1032. doi: 10.1038/jid.2014.532. Epub 2014 Dec 19.

30.

Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.

Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, Tüting T.

Cancer Discov. 2014 Jun;4(6):674-87. doi: 10.1158/2159-8290.CD-13-0458. Epub 2014 Mar 3.

31.

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.

Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M, Gaffal E, Tüting T.

Nature. 2014 Mar 6;507(7490):109-13. doi: 10.1038/nature13111. Epub 2014 Feb 26.

PMID:
24572365
32.

The solid solution series (GeTe)x(LiSbTe2)2 (1 ≤ x ≤ 11) and the thermoelectric properties of (GeTe)11(LiSbTe2)2.

Schröder T, Schwarzmüller S, Stiewe C, de Boor J, Hölzel M, Oeckler O.

Inorg Chem. 2013 Oct 7;52(19):11288-94. doi: 10.1021/ic401516m. Epub 2013 Sep 16.

PMID:
24093486
33.

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel M, Bovier A, Tüting T.

Nat Rev Cancer. 2013 May;13(5):365-76. doi: 10.1038/nrc3498. Epub 2013 Mar 28. Review.

PMID:
23535846
34.

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R.

Cell. 2012 Nov 21;151(5):937-50. doi: 10.1016/j.cell.2012.10.035.

35.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
36.

Myb-binding protein 1a (Mybbp1a) regulates levels and processing of pre-ribosomal RNA.

Hochstatter J, Hölzel M, Rohrmoser M, Schermelleh L, Leonhardt H, Keough R, Gonda TJ, Imhof A, Eick D, Längst G, Németh A.

J Biol Chem. 2012 Jul 13;287(29):24365-77. doi: 10.1074/jbc.M111.303719. Epub 2012 May 29.

37.

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK.

Clin Cancer Res. 2011 Dec 1;17(23):7394-401. doi: 10.1158/1078-0432.CCR-11-1648. Epub 2011 Sep 26.

38.

The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword.

Hölzel M, Burger K, Mühl B, Orban M, Kellner M, Eick D.

Oncotarget. 2010 May;1(1):43-7.

39.

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R.

Cell. 2010 Jul 23;142(2):218-29. doi: 10.1016/j.cell.2010.06.004.

40.

Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.

Burger K, Mühl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, Kellner M, Gruber-Eber A, Kremmer E, Hölzel M, Eick D.

J Biol Chem. 2010 Apr 16;285(16):12416-25. doi: 10.1074/jbc.M109.074211. Epub 2010 Feb 16.

41.

Defects in 18 S or 28 S rRNA processing activate the p53 pathway.

Hölzel M, Orban M, Hochstatter J, Rohrmoser M, Harasim T, Malamoussi A, Kremmer E, Längst G, Eick D.

J Biol Chem. 2010 Feb 26;285(9):6364-70. doi: 10.1074/jbc.M109.054734. Epub 2010 Jan 7.

42.

The CALM and CALM/AF10 interactor CATS is a marker for proliferation.

Archangelo LF, Greif PA, Hölzel M, Harasim T, Kremmer E, Przemeck GK, Eick D, Deshpande AJ, Buske C, de Angelis MH, Saad ST, Bohlander SK.

Mol Oncol. 2008 Dec;2(4):356-67. doi: 10.1016/j.molonc.2008.08.001. Epub 2008 Sep 4.

43.

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R.

Cancer Cell. 2009 Apr 7;15(4):328-40. doi: 10.1016/j.ccr.2009.02.023.

44.

Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.

Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Hölzel M, Eick D, Zimber-Strobl U, Strobl LJ.

Blood. 2009 May 28;113(22):5506-15. doi: 10.1182/blood-2008-11-190090. Epub 2009 Apr 1.

45.

c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08. Epub 2009 Mar 4.

46.

c-MYC impairs immunogenicity of human B cells.

Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.

Adv Cancer Res. 2007;97:167-88. Review.

PMID:
17419945
47.

Interdependence of Pes1, Bop1, and WDR12 controls nucleolar localization and assembly of the PeBoW complex required for maturation of the 60S ribosomal subunit.

Rohrmoser M, Hölzel M, Grimm T, Malamoussi A, Harasim T, Orban M, Pfisterer I, Gruber-Eber A, Kremmer E, Eick D.

Mol Cell Biol. 2007 May;27(10):3682-94. Epub 2007 Mar 12.

48.

C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.

Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, Bornkamm GW.

Int J Cancer. 2007 Apr 1;120(7):1387-95.

49.

The BRCT domain of mammalian Pes1 is crucial for nucleolar localization and rRNA processing.

Hölzel M, Grimm T, Rohrmoser M, Malamoussi A, Harasim T, Gruber-Eber A, Kremmer E, Eick D.

Nucleic Acids Res. 2007;35(3):789-800. Epub 2006 Dec 22.

50.

Rapid conditional knock-down-knock-in system for mammalian cells.

Hölzel M, Rohrmoser M, Orban M, Hömig C, Harasim T, Malamoussi A, Gruber-Eber A, Heissmeyer V, Bornkamm G, Eick D.

Nucleic Acids Res. 2007;35(3):e17. Epub 2006 Dec 14.

Supplemental Content

Loading ...
Support Center